NEUROSCIENCE ASSOCIATES INC

Neuroscience Associates Inc. specializes in preclinical and translational research focused on neuroimaging biomarkers for neurotoxicity, with a demonstrated capability in advanced MRI-based analytics to detect and quantify brain injury pathways. Their technical expertise centers on developing and validating molecular and functional imaging targets that enable early detection of neurotoxic insults, supporting drug development and safety assessment in biomedical research. The company applies rigorous neuroscientific methodologies to bridge laboratory findings with clinical relevance, particularly in contexts involving environmental or pharmacological neurotoxicants. Their approach integrates signal processing, quantitative imaging analysis, and biological validation to deliver actionable insights for neuropharmacology and neuroprotection studies. The contractor has performed research services for the Department of Health and Human Services, primarily supporting initiatives aimed at identifying objective biomarkers of brain toxicity. This engagement reflects a focused partnership in advancing neuroimaging tools for public health surveillance and toxicological evaluation, suggesting alignment with HHS agencies such as NIH or FDA in supporting neuroscience-driven regulatory science. Neuroscience Associates Inc. operates exclusively within NAICS 541714, which defines research and development in biotechnology excluding nanobiotechnology. This positions them as a niche provider in neurobiological R&D, specializing in non-nanotech-based biomarker discovery for neurological disorders and neurotoxic exposure. Their market focus is on federal-funded neuroscience research programs requiring validated, reproducible imaging endpoints. As a small business structured as a 2L entity based in Knoxville, Tennessee, the company maintains a lean, research-driven operational model. While no federal certifications are disclosed, their work demonstrates technical rigor in neuroimaging and biotechnology research, aligning them with government-funded biomedical innovation initiatives. Their geographic presence supports regional access to academic and clinical research partners in the Southeast.